Matutino A, Joy A A, Brezden-Masley C, Chia S, Verma S
Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB.
Department of Oncology, Division of Medical Oncology, University of Alberta, Cross Cancer Institute, Edmonton, AB.
Curr Oncol. 2018 Jun;25(Suppl 1):S131-S141. doi: 10.3747/co.25.4000. Epub 2018 Jun 13.
Estrogen receptor modulators and estrogen deprivation have become standards of care for hormone receptor-positive metastatic breast cancer. However, after traditional first-line endocrine monotherapy treatment, the disease typically progresses despite the initial high rate of clinical benefit. Multiple studies have aimed at optimizing treatment strategies to improve upon clinical benefit beyond the traditional single-agent endocrine treatment. With the availability of new data and novel therapies, the clinical practice challenge becomes how best to define the optimal treatment sequence to maximize clinical benefit. In this review, we present treatment options clinically relevant to the management of hormone-positive, her2-negative metastatic breast cancer, and we propose a treatment algorithm based on the current literature.
雌激素受体调节剂和雌激素剥夺疗法已成为激素受体阳性转移性乳腺癌的标准治疗方法。然而，在传统的一线内分泌单药治疗后，尽管初始临床获益率较高，但疾病通常仍会进展。多项研究旨在优化治疗策略，以在传统单药内分泌治疗的基础上提高临床获益。随着新数据和新疗法的出现，临床实践面临的挑战变成了如何最好地确定最佳治疗顺序以最大化临床获益。在本综述中，我们介绍了与激素阳性、HER2阴性转移性乳腺癌管理临床相关的治疗选择，并根据当前文献提出了一种治疗算法。
